Phase III trial finds no survival benefit from adding chemotherapy to surgery for peritoneal metastases

◆ TRIAL DATA

The CAIRO6 trial (351 patients) found that perioperative systemic therapy did not significantly improve overall survival compared to surgery alone in patients with resectable peritoneal-only metastases (44 vs 39 months median survival, P = .28). (The Lancet Oncology)